TIL Stock Discussion
Instil Bio, Inc. Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Cancer Immunotherapy Cell Therapy Non Small Cell Lung Cancer Melanoma Lymphocytes Cervical Cancer Head And Neck Squamous Cell Carcinoma Tumor Infiltrating Lymphocytes Cutaneous Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Popular Now
Featured Articles